NBP 6-K
NovaBridge Biosciences (NBP)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of August
Commission File Number:
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
1
NovaBridge Reports Financial Results for the Six Months Ended June 30, 2026
NovaBridge Biosciences (“NovaBridge”) is furnishing this report on Form 6-K to provide its unaudited condensed consolidated financial statements as of June 30, 2026 and December 31, 2025, and for the six months ended June 30, 2026 and 2025 and to provide Management’s Discussion and Analysis of Financial Condition and Results of Operations with respect to such financial statements.
On August 20, 2026, NovaBridge issued a press release regarding its unaudited financial results for the six months ended June 30, 2026 and provided an update on recent business developments, which is attached to this Form 6-K as Exhibit 99.1. The unaudited condensed consolidated financial statements as of June 30, 2026 and December 31, 2025, and for the six months ended June 30, 2026 and 2025 are attached to this Form 6-K as Exhibit 99.2. Management’s Discussion and Analysis of Financial Condition, Results of Operations, and Disclosures on Controls and Procedures is attached to this Form 6-K as Exhibit 99.3.
The information in this report on Form 6-K shall be deemed to be incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File No. 333-286954) and Form S-8 (File Nos. 333-239871, 333-265684, 333-256603, 333-279842, 333-290195 and 333-298369) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
Exhibit |
|
Title |
|
||
|
||
|
||
101 |
|
The following materials from NovaBridge’s Report on Form 6-K for the six months ended June 30, 2026 formatted in XBRL (eXtensible Business Reporting Language): (i) the Unaudited Condensed Consolidated Balance Sheets, (ii) the Unaudited Condensed Consolidated Statements of Comprehensive Loss, (iii) the Unaudited Condensed Consolidated Statements of Changes in Shareholders’ Equity, (iv) the Unaudited Condensed Consolidated Statements of Cash Flows, and (v) Notes to the Unaudited Condensed Consolidated Financial Statements. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
NovaBridge Biosciences |
||
|
|
||
|
By |
: |
/s/ Kyler Lei |
|
Name |
: |
Kyler Lei |
|
Title |
: |
Chief Financial Officer |
Date: August 20, 2026
3